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2356The prognosis of patients with
hematological malignancies has
improved because of the use
of new chemotherapeutic and
antineoplastic drugs and more
dose-intensive regimens (1). None-
theless, novel therapy has been
associated with signiﬁcant ad-
verse events such as cardiac
toxicity (2). In addition to an-
thracyclines, several other drugs
used in the treatment plans of
hematologic malignancies, either
at standard doses during front-
line therapy or as part of high-
dose conditioning regimens for
hematopoietic stem-cell trans-
plantation (HSCT), may induce
cardiac toxicity (2) through adiversity of mechanisms including endothelial toxicity and
direct myocyte injury (3–5). Even in asymptomatic
patients, left ventricular systolic dysfunction (LVSD)
might limit patients’ treatment options and their long-term
survival, because a signiﬁcant proportion of them will
relapse after front-line therapy and will require further
salvage treatment, including HSCT in most instances (3).page 2363Angiotensin-converting enzyme inhibitors (ACEI) have
been demonstrated to slow the progression of LVSD and
to prevent heart failure in asymptomatic high-risk patients
(6) and to decrease mortality in post-infarction patients
with LVSD and in patients with heart failure (6),
including patients with anthracycline-induced cardiomy-
opathy (7). ACEI therapy has also been shown to have
preventive effects against chemotherapy-induced car-
diotoxicity in animal models (8,9) and in adult patients
with early cardiotoxicity (10). Similar results have been
obtained with the administration of beta-blockers in
patients with post-infarction LVSD or heart failure (6), in
animal models of cardiotoxicity (11,12) and in patients
treated with anthracyclines (13,14). In addition, admin-
istration of both ACEI and beta-blockers has been shown
to have additive beneﬁcial effects in patients with LVSD
(15) and is the recommended treatment in current
guidelines (6).
Therefore, we designed the OVERCOME (preventiOn
of left Ventricular dysfunction with Enalapril and caRvedilol
in patients submitted to intensive ChemOtherapy for the
treatment of Malignant hEmopathies) study to evaluate the
effect of enalapril and carvedilol on the prevention of LVSD
in patients with malignant hemopathies undergoing inten-
sive chemotherapy (16).Methods
Trial. This was a prevention, randomized, controlled trial
performed at the Hospital Clinic of Barcelona, Spain. All
patients were informed orally and in writing, and all gave
their written consent before inclusion. The protocol was
approved by the ethics committee of our institution, which
recommended an open-label design of the study, considering
the pilot nature of the trial, the severity of the treated
diseases, the high incidence of infectious complications, and
the potential hypotensive effect of the intervention. The
study was conducted according to the Helsinki Declaration
and registered with U.S. National Institutes of Health
National Clinical Trials (NCT01110824).
Population of the study. Inclusion criteriawere adult patients
from 18 to 70 years old, in sinus rhythm and with normal
echocardiographic LV ejection fraction (LVEF50%), recently
diagnosed with acute leukemia and referred for immediate
intensive chemotherapy, and patients with relapsed or refractory
Hodgkin and non-Hodgkin lymphoma and multiple myeloma
undergoing autologous HSCT.
Exclusion criteria were the presence of congestive heart
failure; LVEF <50%; prior myocardial infarction or docu-
mented coronary artery disease; signiﬁcant valvulopathy or
myocardiopathy; renal failure (deﬁned as an estimated
glomerular ﬁltration rate of <30 ml/h/m2); hepatocellular
insufﬁciency or grade III to IV increase of liver enzymes not
secondary to tumoral liver inﬁltration; ongoing or expected
need to be treated with ACEI, angiotensin II receptor
blockers (ARB), or beta-blockers; prior allergy to ACEI or
ARB; systolic blood pressure (SBP) lower than 90 mm Hg;
asthma; atrioventricular block or sinus bradycardia (heart rate
lower than 60 beats/min); persistent atrial ﬁbrillation; need to
be treated with a class I antiarrhythmic drug; pregnancy; and
inability or unwillingness to give informed consent.
Randomization. Participants were randomly assigned in
a 1:1 ratio to receive (the intervention group) or not to
receive (the control group) enalapril and carvedilol.
Randomization was centralized and performed by the
hospital’s Clinical Trials Unit, based on a series of random
numbers generated by a computer program in blocks of
random size and stratiﬁed by the patient cohort: acute
leukemia versus other malignant hemopathies undergoing
autologous HSCT.
Study treatment. Enalapril and carvedilol was started
simultaneously at least 24 h before the ﬁrst cycle of chemo-
therapy. The initial dose of enalapril was 2.5 mg twice daily
(1.25 mg in patients with SBP between 90 mm Hg and
100 mm Hg) and was increased gradually every 3 to 6 days
under close supervision to 5 mg and 10 mg twice daily if SBP
persistently remained >90 mm Hg and creatinine levels
were <2.5 mg/dl (or increased <25% in patients with creat-
inine levels of >1.3 mg/dl). In case of hypotension, the dose
was reduced to the closest level or stopped, and the lowest dose
was resumed when SBP persistently remained >90 mm Hg.
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2357The initial dose of carvedilol was 6.25 mg twice daily and
increased gradually every 3 to 6 days to 12.5 mg and 25 mg
twice daily in the absence of clinical signs of congestive
heart failure, sinus bradycardia <60 beats/min or any degree
of atrioventricular block. In the case of hypotension or
bradycardia, the dose was also reduced to the closest level.
All patients received in-hospital chemotherapy according
to the protocols of our institution (Online Table 1), and
HSCT was performed using peripheral blood as stem cell
source (PBSCT). The admission period was prolonged
throughout the induction phase in patients with acute
leukemia or the whole procedure in patients undergoing
autologous PBHSCT until hematologic recovery, with
a mean length of 30 days after inclusion in the trial. After
completion of therapy, patients were followed in an outpa-
tient clinic where enalapril and carvedilol were provided
directly to the patients and they were evaluated at the end of
the follow-up period, 6 months after randomization.
Endpoints. The primary outcome measure was the change
from baseline in global LVEF, measured by echocardiog-
raphy and by cardiac magnetic resonance (CMR) imaging,
6 months after randomization.
Secondary outcome measures included a predeﬁned
subgroup analysis of the results according to the patient cohort
(acute leukemia vs. other malignant hemopathies) and to TnI
and B-type natriuretic peptide (BNP) levels, the incidence of
an absolute decrease in LVEF 10% units associated with
a decline below its normal limit of 50%; the incidence of
death, heart failure, or signiﬁcant LVSD as deﬁned by an
LVEF <45%; diastolic function, measured by Doppler
echocardiography; and the incidence of severe life-threatening
adverse events.
Six-month studies were performed when patients were in
stable condition, otherwise, the study was delayed until the
patient’s recovery. All outcomes were assessed by independent
investigators blinded to the patient’s condition and allocated
treatment. If suspected congestive heart failure occurred in
any of the two arms during the study, a complete cardiac
evaluation was performed, including a clinical echocardio-
graphic study to conﬁrm the diagnosis. If LV dysfunction was
conﬁrmed, the patients were considered to have achieved the
endpoint of the study and were treated with ACEI and/or
beta-blockers according to the treating physician’s criteria.
Echocardiography. Echocardiographic-Doppler studies were
performed with a commercially available system (Vivid 7;
General Electric Medical System, Milwaukee, Wisconsin).
Images were digitally stored for later off-line analysis with
speciﬁc software (EchoPac, General Electric). LVEF was
calculated using the Simpson method. Contrast-enhanced
echocardiography was performed when the endocardial
border visualization was not optimal. LV diastolic function
was assessed in terms of LV inﬂow diastolic velocities,
pulmonary vein ﬂow, and lateral mitral annulus motion (17).
Early (E) and late (A) peak diastolic velocities of LV inﬂow
and the deceleration time (DT) of the E wave were deter-
mined by pulsed-wave Doppler, and the E/A ratio wascalculated. Pulmonary vein ﬂow peak systolic (S) and diastolic
(D) velocities were determined by pulsed-wave Doppler and
the S/D ratio was calculated. The early peak diastolic velocity
of the mitral annulus (Em) was determined using pulsed-wave
Doppler tissue imaging, and the ratio E/Emwas calculated as a
surrogate for LV ﬁlling pressure. The left atrial area was also
measured. All echocardiograms were interpreted blindly by a
cardiologist unaware of the patient’s condition and treatment.
Cardiac magnetic resonance imaging. CMR studies were
carried out with a 1.5-T Sigma HD-x scanner (General
Electric) under electrocardiographic gating conditions and
using a cardiac phased-array surface coil. Global LV systolic
function was assessed with a standard steady-state free
precession cine sequence in sequential 10-mm thick short
axis slices.
Identifying data were removed from CMR images for
analysis. An experienced observer masked to patient treat-
ment allocation and imaging point (baseline or end of the
study) performed manual planimetry of the endocardial
border at end-systolic and end-diastolic frames to compute
LVEF, using commercially available software (Report card,
General Electric).
TnI and BNP measurements. TnI was measured before,
daily during each cycle of chemotherapy, and 12 and 24 h after
each cycle. BNP concentrations were determined before
and 12 h after each cycle of chemotherapy and following
infusion of harvested HSCT. For each patient, only the
highest TnI and BNP values were considered. Plasma levels
of TnI were measured using a ﬂuorometric enzyme immuno-
assay analyzer (Tn I-Ultra; Advia Centaur CP) with a func-
tional sensitivity of 0.006 ng/ml and a cutoff level of 0.04 ng/ml
corresponding to the 99th percentile of control values. BNP
was measured using a chemiluminometric immunoassay run
on the Advia Centaur Immunochemistry analyzer (Siemens
Healthcare Diagnostics, Tarrytown, New York).
Sample size and statistical analysis. To detect an inter-
group difference of 5 points in LVEF change from baseline
to follow-up with a statistical power of 90%, a type I
error risk of 5%, and an estimated SD of 6.5%, a total of
72 patients was estimated to be needed on the basis of a two-
sided, two-sample Student t test. Assuming a 20% rate of
incomplete measurements, a total of 90 patients was needed
to be enrolled in the study.
All statistical analyses of the results were performed by the
intention-to-treat method. Comparisons of baseline charac-
teristics and incidence of clinical events between the inter-
vention and control groups were performed with the unpaired
Student t test, chi-square test, and Fischer exact test. BNP
data were reported as medians (25th, 75th percentiles) and
compared using the Mann-Whitney U test; the Spearman
rank correlation test was used to correlate peak BNP levels and
ﬁnal LVEF. Differences between the two groups in terms
of absolute changes in LVEF from baseline to 6 months
after randomization were compared ﬁtting mixed models
for repeated measures with the (co)variance type set to
unstructured. A sensitivity analysis was also conducted before
Table 1 Baseline Clinical Differences Between Groups
Intervention
(n ¼ 45)
Control
(n ¼ 45) p Value
Age (yrs) 49.7  13.9 50.9  13.2 0.67
Women (%) 18 (40) 21 (47) 0.52
BSA (m2) 1.86  0.26 1.83  0.21 0.62
Hypertension (%) 6 (13) 8 (18) 0.77
Hypercholesterolemia (%) 7 (16) 3 (7) 0.32
Statin treatment (%) 4 ( 9) 2 ( 4) 0.68
Diabetes (%) 3 (7) 1 (2) 0.62
Smokers (%) 13 (29) 4 (9) 0.03
Patient cohort (%) 1.00
Acute leukemia 18 (40) 18 (40)
Autologous PBSCT 27 (60) 27 (60)
SBP (mm Hg) 118  17 118  16 1.00
DBP (mm Hg) 73  12 74  10 0.66
HR (beats/min) 75  12 78  13 0.24
eCCr (ml/min) 105  30 100  30 0.30
Hemoglobin, g/l 107.8  17 108  20 0.97
TnI (ng/ml) 0.013  0.008 0.013  0.010 0.80
BNP (ng/l) 19 (9, 38) 21 (12, 35) 0.88
LVEF (%) 62  5.9 63  5.9 0.50
Values are mean  SD or n (%).
BNP ¼ brain natriuretic peptide; BSA ¼ body surface area; DBP ¼ diastolic blood pressure;
eCCr ¼ estimated creatinine clearance rate by the Cockcroft-Gault formula; HR ¼ heart rate;
HSCT ¼ hematopoietic stem cell transplantation; LVEF ¼ left ventricular ejection fraction; SBP ¼
systolic blood pressure; TnI ¼ troponin I.
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2358ﬁtting themodel by imputing a conservative value based on the
10th percentile of the overall response to those patients with
missing values.
A pre-speciﬁed analysis included assessment of the
primary outcome separately for patients with acute leukemia
and for patients with lymphoma or multiple myeloma
undergoing autologous PBSCT. The level of signiﬁcance
was set at the standard two-sided level of 5%. All analyses
were performed using SAS version 9.1.3 software (SAS
Institute Inc., Cary, North Carolina).
Results
Patients. From May 2008 to June 2010, 114 consecutive
patients potentially eligible for the study were assessed, of
whom 111 met inclusion criteria and 21 had some exclusion
criteria. Forty-ﬁve of the resulting 90 patients were
randomized to the intervention group and 45 to the control
group (Fig. 1). The mean age of the patients was 50  13
years of age, and 43% were women. Thirty-six patients had
acute leukemia (of myeloid lineage in 30 and lymphoblastic
in 6), and 54 had other malignancies undergoing PBSCT
(9 with Hodgkin disease, 23 with non-Hodgkin lymphoma,
and 22 with multiple myeloma).
The 2 groups were well balanced with respect to baseline
characteristics and treatment received prior to and during
the study, including anthracycline dose, except for the
prevalence of smokers and of prior treatment with radio-
therapy who were more frequent in the intervention group
(Tables 1 and 2).
Study drugs. In the intervention group, the mean dose per
patient per day of enalapril and carvedilol was 8.2  5.9 mgFigure 1 Flow Diagram of the OVERCOME Study
A total of 81% of all eligible patients during a 2-year period were enrolled
in the study and were randomized to the intervention or control group.
ACEI ¼ angiotensin-converting enzyme inhibitor.and 26.1  18.2 mg, respectively, at 30 days, and 8.6 
5.9 mg and 23.8  17 mg, respectively, at the end of the
study. The maximum administered doses were 10.9 
5.9 mg/day for enalapril and 33.4 16 mg/day for carvedilol.
Primary endpoint. Thirteen patients discontinued the
study because of death in 11 patients and clinical heart
failure in 2 patients. In those two patients, a ﬁnalTable 2
Anticancer Treatment Received by Patients Prior to
and During the Study Period
Intervention
(n ¼ 45)
Control
(n ¼ 45) p Value
Radiotherapy
Prior (%) 6 (13) 2 (4) 0.27
During study (%) 6 (13) 2 (4) 0.27
Total (%) 12 (27) 4 (9) 0.05
Chemotherapy
Prior (%) 27 (60) 27 (60) 1.00
No. of lines of therapy 1.4  1.6 1.6  1.9 0.47
During study 45 (100) 45 (100) 1.00
No. of cycles 1.73  1.5 1.44  0.8 0.27
Anthracyclines
Prior (%) 19 (42) 17 (38) 0.67
Dose (mg/m2) 151  208 108  150 0.26
During study (%) 18 (40) 18 (40) 1.00
Dose (mg/m2) 139  188 133  182 0.87
Total (%) 37 (82) 35 (78)
Dose (mg/m2) 290  189 241  162 0.15
HSCT during study (%) 37 (82) 34 (78) 0.76
Values are n (%) or mean  SD.
HSCT ¼ hematopoietic stem cell transplantation.
Table 3 Differences in Change in LVEF Between the Intervention and Control Groups
Enalapril þ Carvedilol Control Intergroup Difference p Value
Echocardiography
LVEF ( %) n ¼ 42 n ¼ 37
Baseline 61.67  5.11 62.59  5.38
6 months 0.17 (2.24 to 1.90) 3.28 (5.49 to 1.07) 3.11 (6.10 to 0.11) 0.04
CMR
LVEF ( %) n ¼ 31 n ¼ 27
Baseline 56.00  6.00 60.18  7.16
6 months 0.36 (2.41 to 3.13) 3.04 (6.01 to 0.07) 3.40 (7.43 to 0.63) 0.09
Values are mean  SD or mean (95% conﬁdence interval) 6-month change from baseline in absolute LVEF.
CMR ¼ cardiomagnetic resonance imaging; LVEF ¼ left ventricular ejection fraction.
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2359echocardiographic study was obtained, resulting in 79
patients (88%) with complete echocardiographic data.
Echocardiographic LVEF was similar in the intervention
and control groups at baseline. At 6 months, while no serial
changes were observed in the intervention group, patients in
the control group had a decrease in their mean LVEF that
resulted in a global absolute intergroup difference of 3.11
points (p ¼ 0.04) (Table 3).
Complete CMR studies could be obtained in only 58
patients (64%). Four patients refused to perform the baseline
study and 28 did not perform the 6-month evaluation
because of death in 11 patients, heart failure in 2 patients,
and cancer progression and patient’s refusal in 17 patients.
Mean LVEF did not change in the intervention group but
decreased by 3.04 absolute percentage points in the control
group, resulting in a 3.40 absolute percentage intergroup
difference (p ¼ 0.09) (Table 3).
When a sensitive analysis was performed imputing
the values of the 10th percentile to those patients with
missing values, similar results were observed, with an
estimated 3.61 (95% CI: 6.45 to 0.77) intergroupFigure 2 Change From Baseline in LVEF in Acute Leukemia Patients
While no differences were observed in the intervention group, patients in the control group
(p ¼ 0.025), with all but 3 patients having some degree of LVEF reduction. Values are mabsolute difference in echocardiographic LVEF (p ¼ 0.013)
and a 2.96 (95% CI: 6.08 to 0.16) difference in CMR
LVEF (p ¼ 0.063).
Secondary endpoints: disease category: acute leukemia
versus autologous PBSCT. An interaction was observed
in the echocardiographic LVEF results according to the
disease category (p for interaction ¼ 0.08), with more
marked differences in patients treated for acute leukemia
than in patients undergoing an autologous PBSCT. The
mean intergroup difference in LVEF was of 6.38 (95%
CI: 11.88 to 0.87, p ¼ 0.025) absolute percent points in
patients with acute leukemia (Fig. 2), and of 1.01 (95%
CI: 4.46 to 2.45, p ¼ 0.56) in patients with other
malignancies undergoing PBSCT.
LV diastolic function. Baseline parameters of diastolic
function were suggestive of normal to mild abnormal
relaxation consistent with the mean age of the patients, with
no left atrial enlargement, E/A ratio close to 1 and S/D ratio
of pulmonary veins over 1. No signiﬁcant changes in the
diastolic parameters were observed in any of the groups at
follow-up (Online Table 2).Undergoing Chemotherapy in the Intervention and Control Groups
had a 6.7% absolute decrease in their mean left ventricular ejection fraction (LVEF)
ean  SEM.
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2360Biomarkers. Eleven patients (10 with acute leukemia and
only 1 patient undergoing PBSCT, p < 0.001) experienced
TnI elevation during chemotherapy: 7 in the intervention
and 4 in the control group (p ¼ 0.52). Nine of the 11
patients with positive troponin levels had TnI elevation at
the end or early after a cycle of chemotherapy: 5 during the
initial frontline therapy and 4 at 1 month later. Only 2
patients had troponin elevation both during initial treatment
and 1 month later. The degree of TnI elevation was mild,
and only 3 patients had TnI elevation over three times the
upper reference limit. Recurring TnI elevation (2 episodes)
occurred in 6 patients, with 3 patients in each study group.
No interaction was found between the effects of enalapril
and carvedilol on LVEF and TnI elevation (p ¼ 0.59).
BNP elevation over 80 ng/l was common and occurred
in 17 (47%) patients with acute leukemia and 24 (44%)
patients undergoing HSCT, with no differences between the
intervention and the control groups (53% versus 38%,
p ¼ 0.14). BNP elevation over 200 ng/l occurred in 7 and 2
patients, respectively (p ¼ 0.16). No correlation was found
between peak BNP levels and the change in LVEF
(R ¼ 0.11, p ¼ 0.34).
Clinical endpoints. During the study period, 14 patients
withdrew prematurely from the study because of death in 11
patients (cancer-related in 4 and infection-related in 7),
heart failure in 2, and cancer progression in 1 patient. Five of
7 patients who died from an infectious cause were allocated
to the control group. Patients who survived a septic episode
during the trial experienced a mean decrease in ﬁnal
LVEF of 4.6  9 absolute points, compared to a decrease of
0.6  6 points in patients without sepsis (p ¼ 0.04).
Compared to controls, the intervention group had a lower
incidence of premature end of the study (6.7% vs. 24.4%,
respectively, p ¼ 0.02), of death or heart failure (6.7% vs.
22.2%, respectively, p ¼ 0.036), and of the pre-speciﬁed
secondary endpoint of death, heart failure or a ﬁnal LVEF
of <45% (6.7% vs. 24.4%, respectively, p ¼ 0.02; Table 4).
Patients treated with enalapril and carvedilol also showed
a trend toward a lower incidence of heart failure or a >10%
decrease in LVEF (9.5% vs. 19%, respectively, p ¼ 0.22).
Safety. Globally, enalapril and carvedilol were well toler-
ated, although the dose of each drug had to be adjusted
frequently according to the global patient status. During the
ﬁrst 30 days, enalapril was stopped in 3 patients, carvedilolTable 4 Clinical Endpoints
En
Premature end of the study (%)
Total mortality (%)
Death or heart failure (%)
Death, heart failure or ﬁnal LVEF<45% (%)
10% decrease in LVEF with a ﬁnal LVEF<50% (%)
Heart failure or 10% decrease in LVEF (%)
Severe adverse events* (%)
Values are n (%). *Deﬁned as a serious adverse event that resulted in death
LVEF ¼ left ventricular ejection fraction.in 2, and both drugs in 1 patient, while transient discon-
tinuation was indicated in 1, none, and 2 patients, respec-
tively. New transient discontinuation frequency for the
period of 1 to 6 months was indicated in 3, 2, and 3 patients,
respectively.
Nine patients (20%) in the intervention group and 15
(33%) in the control group had life-threatening adverse
events (p ¼ 0.15) (Table 4). All of them were related to
sepsis and required admission to an intensive care unit.
None of the severe adverse effects that occurred in the inter-
vention group were related to the treatment with enalapril
and carvedilol.
Discussion
The OVERCOME study has shown that the concomitant
treatment with enalapril and carvedilol may prevent LVSD
in patients with malignant hemopathies treated with high-
dose chemotherapy regimens. The results were consistent
as measured with two-dimensional echocardiography or
CMR, although the lower number of patients studied with
the latter method precluded obtaining a conventional
signiﬁcant statistical difference. In addition, clinical events
were less frequent in patients treated with the car-
dioprotective drugs. These results could have important
clinical implications.
Comparison with other studies. Most studies of
chemotherapy-induced cardiotoxicity have focused on the
treatment of patients with heart failure or LVSD (2,7,18). In
these patients, the current clinical practice is to stop
chemotherapy and to restart it after LV recovery and to
avoid further use of anthracyclines. However, even if LVSD
improves after treatment, patients with chemotherapy-
induced cardiotoxicity are prone to further deterioration in
their LV function when confronted with further cycles of
chemotherapy or even under stress conditions (19). Hence,
in patients with cancer, the main objective should be to
prevent rather than to treat cardiac toxicity (20).
ACEI have been shown to be effective against
chemotherapy-induced cardiotoxicity in animal models
(8,9). Although their use to prevent the progression of
LVSD was disappointing in a study of pediatric cancer
(18), a recent study reported favorable results when ad-
ministered to adult patients with chemotherapy-inducedalapril þ Carvedilol Control p Value
3 (6.7) 11 (24.4) 0.02
3 (6.7) 8 (17.8) 0.11
3 (6.7) 10 (22.2) 0.036
3 (6.7) 11 (24.4) 0.020
2 (4.8) 2 (5.4) 0.90
4 (9.5) 7 (19) 0.22
9 (20) 15 (33) 0.15
or was life-threatening.
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2361cardiac toxicity (10). Positive results have been also ob-
tained with the administration of beta-blockers in animal
models of chemotherapy-induced cardiomyopathy (11,12),
and in two pilot studies of patients undergoing treatment
with anthracyclines (13,14).
The magnitude of the results of our study was mild, with
a 3.1% absolute difference in the mean LVEF between the
intervention and control groups in the global population.
Nevertheless, these results include very different individual
responses and are in accordance with the results obtained in
large clinical trials in which a 20% relative risk reduction is
sought (6). Other studies have reported a higher effect of
cardioprotection strategies. In the study performed by
Cardinale et al. (10), 43% of the control and none of the
enalapril group had a drop of more than 10% in LVEF,
while heart failure occurred in 24% and 0%, respectively.
Differences in the patient population, the intensity and
type of chemotherapy, and the protocol design of both
studies may explain these different results. Thus, the
OVERCOME trial included patients with normal LVEF
and normal troponin levels, whereas the study by Cardinale
et al. (10) included only patients who experienced troponin
elevation after high-dose chemotherapy, 44% of whom had
persistent troponin elevation 1 month after randomization,
representing a population with demonstrated chemotherapy-
induced cardiotoxicity and at a much higher risk of
chemotherapy-induced LVSD. In the study by Kalay et al.
(13), in which low-dose carvedilol was administered, the
patient population was markedly different: most patients
were being treated for breast cancer, and all patients received
high doses of anthracyclines.
Although, almost half of the patients presented elevated
peak BNP levels, no intergroup differences were observed,
and no correlation existed between LVEF reduction and
BNP elevations. Many factors not directly related to cardiac
toxicity might account for these ﬁndings, such as hyper-
hydration to prevent renal dysfunction and bladder toxicity
during chemotherapy administration, repeated packed red
cells and platelet transfusions, severe anemia, hypotension,
acute kidney injury, or frequent infection episodes (21).
Effect on patients with acute leukemia. In our study, the
effects were more pronounced in patients treated for
recently diagnosed acute leukemia than for patients under-
going autologous PBSCT, with a mean 6.4% absolute
difference in LVEF in the former group. Although this was
a subgroup analysis, it was pre-speciﬁed in the study
protocol and the randomization of the patients was stratiﬁed
for this condition. In addition, an interaction was found
between the effect of the intervention and the cohort of
patients. These results are also in agreement with the type of
the chemotherapy administered, which included several
multiagent chemotherapy courses and repeated doses of
anthracyclines in all patients of the acute leukemia group.
On the contrary, patients allocated to the PBSCT cohort
received only one chemotherapy course, the conditioning
regimen, without anthracycline agents. Accordingly, thenumber of patients with troponin elevation during treat-
ment was much higher in the acute leukemia group,
reﬂecting the higher cardiotoxic effect of the chemotherapy
administered to these patients.
Diastolic function. Although we found signiﬁcant changes
in LVEF, an accepted measure of global LV systolic func-
tion, we did not ﬁnd differences in LV indices of diastolic
function. A recent study of carvedilol has reported similar
results (14). The high variability of these measurements and
their strong dependence on nonspeciﬁc and transient
hemodynamic factors is a recognized limitation of these
measurements. In addition, ACEI and beta-blockers have
not been shown to be efﬁcacious in patients with heart
failure and preserved ejection fraction (6).
Effects on clinical events. The patients in the intervention
group had a lower incidence of premature discontinuation of
the study for any reason, of death or heart failure, and of
death, heart failure, or signiﬁcant LVSD. As two-thirds of
all deaths were related to infectious complications in the
context of post-chemotherapy neutropenia, it is difﬁcult to
elucidate whether enalapril and carvedilol could have inﬂu-
enced mortality. Considering that patients who survived
septic complications experienced a signiﬁcant reduction in
their LVEF at the end of the study, when they were in
a stable condition, and that LV function is a well-known
determinant of survival in patients with sepsis (22), it
could be speculated that the study intervention might have
inﬂuenced mortality by impacting on the outcome of severe
infectious episodes. Globally, these ﬁndings reinforce the
importance of the results on LVEF.
Compliance and safety. Although drug dose titration had
to be adjusted frequently according to the global patient’s
status, enalapril was stopped in only 3 patients, carvedilol in
2, and both drugs in only 1 patient. In addition, no differ-
ences were observed in the incidence of severe adverse effects
between the intervention and control groups. Thus, the trial
has proved that the combined administration of these drugs
is safe in a setting of intensive therapy for high-risk diseases
with a high myelotoxic potential and frequent development
of infectious complications and hypotensive episodes.
Study limitations. The study was not blinded and placebo
was not administered to the control group because of the
pilot nature of the trial. However, the analyses of the
imaging techniques were blinded, and the study was
randomized and analyzed by the intention-to-treat method
to minimize any possible bias. Complete CMR studies could
only be obtained in 81% of the planned patients. Although
statistical inference with missing data and sensitive analysis
were applied, the CMR results lack enough statistical power
to refuse a type II error. Also, the number of studied patients
limits the value of the interaction found between the effect of
the intervention on LVEF and the disease category. Finally,
the administered doses of enalapril and of carvedilol were
intermediate according to the patient’s clinical condition.
Larger doses could have obtained stronger effects. However,
the doses used were determined by the patient’s status and
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2362safety, and similar to the doses used in large controlled trials
performed in patients with heart failure (6).
Conclusions and clinical implications. This pilot random-
ized trial has proved that the combination of enalapril and
carvedilol prevented LVEF reduction in patients with
diverse hematological malignancies undergoing intensive
chemotherapy. The results of the trial could have important
clinical implications since each year millions of patients with
cancer are treated with chemotherapy worldwide and are
surviving the disease in greater numbers. Nonetheless, the
clinical relevance of this strategy for prevention of
chemotherapy-induced cardiac damage should be conﬁrmed
in larger future studies.
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